Joana Braga Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joana Braga Pereira has a total of 330 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Volpe
University of Gothenburg
21 shared publications - Eric Westman
Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
18 shared publications - Mite Mijalkov
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
16 shared publications Giovanni Volpe
Department of Physics University of Gothenburg Gothenburg Sweden
13 shared publicationsMite Mijalkov
Department of Clinical Neuroscience Division of Neuro Karolinska Institutet Solna Sweden
12 shared publications- Oskar Hansson
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
10 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-14
Mapping the dual functional organization of the substantia nigra
The human substantia nigra (SN) is a central hub for dopaminergic signalling and a key site of pathology in Parkinson’s disease (PD). However, its internal functional organization in human individuals is not well understood. To fill this knowledge gap, here we applied connectopic mapping to the SN in more than 1000 participants from four independent datasets. We identified two main gradients or axes of functional organization within the SN—a mediolateral and a posteroanterior—each showing distinct transcriptomic, behavioural, and pathological associations. Specifically, the mediolateral gradient was related to motor and executive functions, aging and α-synuclein pathology in both PD and Alzheimer’s disease (AD). In contrast, the posteroanterior gradient was linked to memory, anxiety, depression and other neuropsychiatric symptoms in all cohorts. We found gradient-specific associations with gene expression profiles, neurotransmitter maps and cerebrospinal fluid biomarkers that further supported their neurobiological differences. Together, these results reveal a dual-gradient architecture that reflects the functional heterogeneity of the SN and offers new markers, grounded in behaviour and pathology, for stratifying neurodegenerative disease risk in aging, PD and AD.
- 8 September 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-14
Open AccessMapping the dual functional organization of the substantia nigra
The human substantia nigra (SN) is a central hub for dopaminergic signalling and a key site of pathology in Parkinson’s disease (PD). However, its internal functional organization in human individuals is not well understood. To fill this knowledge gap, here we applied connectopic mapping to the SN in more than 1000 participants from four independent datasets. We identified two main gradients or axes of functional organization within the SN—a mediolateral and a posteroanterior—each showing distinct transcriptomic, behavioural, and pathological associations. Specifically, the mediolateral gradient was related to motor and executive functions, aging and α-synuclein pathology in both PD and Alzheimer’s disease (AD). In contrast, the posteroanterior gradient was linked to memory, anxiety, depression and other neuropsychiatric symptoms in all cohorts. We found gradient-specific associations with gene expression profiles, neurotransmitter maps and cerebrospinal fluid biomarkers that further supported their neurobiological differences. Together, these results reveal a dual-gradient architecture that reflects the functional heterogeneity of the SN and offers new markers, grounded in behaviour and pathology, for stratifying neurodegenerative disease risk in aging, PD and AD.
- Open Access
- 1 August 2026
- Published by IOP Publishing in Machine Learning: Science and Technology
- Vol. 7 (4) , 045054
Global graph features unveiled by unsupervised deep learning
Graphs provide a powerful framework for modeling complex systems, but their structural variability poses significant challenges for analysis and classification. To address these challenges, we introduce Graph Autoencoder Uncovering Descriptive Information (GAUDI), an unsupervised graph deep learning framework designed to capture both local details and global structure. GAUDI employs an hourglass architecture with hierarchical pooling and upsampling layers linked through skip connections, which preserve essential connectivity information throughout the encoding–decoding process. Even though identical or highly similar underlying parameters describing a system’s state can lead to significant variability in graph realizations, GAUDI consistently maps them into nearby regions of a structured and continuous latent space, effectively disentangling invariant process-level features from stochastic noise. We demonstrate GAUDI’s versatility across multiple applications, including small-world networks modeling, characterization of protein assemblies from super-resolution microscopy, analysis of collective motion in the Vicsek model, and identification of age-related changes in brain connectivity. Comparison with related approaches highlights GAUDI’s superior performance in analyzing complex graphs, providing new insights into emergent phenomena across diverse scientific domains.
- 1 August 2026
- Published by IOP Publishing in Machine Learning: Science and Technology
- Vol. 7 (4) , 045054
Open AccessGlobal graph features unveiled by unsupervised deep learning
Graphs provide a powerful framework for modeling complex systems, but their structural variability poses significant challenges for analysis and classification. To address these challenges, we introduce Graph Autoencoder Uncovering Descriptive Information (GAUDI), an unsupervised graph deep learning framework designed to capture both local details and global structure. GAUDI employs an hourglass architecture with hierarchical pooling and upsampling layers linked through skip connections, which preserve essential connectivity information throughout the encoding–decoding process. Even though identical or highly similar underlying parameters describing a system’s state can lead to significant variability in graph realizations, GAUDI consistently maps them into nearby regions of a structured and continuous latent space, effectively disentangling invariant process-level features from stochastic noise. We demonstrate GAUDI’s versatility across multiple applications, including small-world networks modeling, characterization of protein assemblies from super-resolution microscopy, analysis of collective motion in the Vicsek model, and identification of age-related changes in brain connectivity. Comparison with related approaches highlights GAUDI’s superior performance in analyzing complex graphs, providing new insights into emergent phenomena across diverse scientific domains.
- Open Access
- 17 April 2026
- Published by Springer Nature in Nature Biomedical Engineering
Three-dimensional quantitative tissue clearing reveals differences in osteovascular niche of aged and young human mesenchymal stromal cells
Human bone marrow mesenchymal stromal/stem cells (BM-MSCs) are widely used in clinical trials and tissue engineering, yet their native microenvironment remains poorly understood. Here we introduce a tissue-clearing protocol, DeepBone, for human bones and integrate it with simultaneous mRNA and protein detection. Using this protocol, we spatially map BM-MSCs relative to key bone microenvironment components, including human blood capillaries, adipocytes, sinusoids and bony trabeculae. Quantitative analysis reveals that the native microenvironment of human BM-MSCs in young bone is enriched in vasculature, sinusoids, bone matrix and adipocytes. In contrast, in aged bone, BM-MSCs show no preferential association with bone or adipocytes. Proliferative BM-MSCs are predominantly found along blood vessels. Moreover, we identify a specialized microenvironment for BM-MSCs in young bone, characterized by sinusoids coiled around trabeculae and enriched by R-type vessels. These findings provide insights into the native niches of BM-MSCs, offering a foundation for the development of tissue engineering strategies that mimic their physiological context.
- 17 April 2026
- Published by Springer Nature in Nature Biomedical Engineering
Open AccessThree-dimensional quantitative tissue clearing reveals differences in osteovascular niche of aged and young human mesenchymal stromal cells
Human bone marrow mesenchymal stromal/stem cells (BM-MSCs) are widely used in clinical trials and tissue engineering, yet their native microenvironment remains poorly understood. Here we introduce a tissue-clearing protocol, DeepBone, for human bones and integrate it with simultaneous mRNA and protein detection. Using this protocol, we spatially map BM-MSCs relative to key bone microenvironment components, including human blood capillaries, adipocytes, sinusoids and bony trabeculae. Quantitative analysis reveals that the native microenvironment of human BM-MSCs in young bone is enriched in vasculature, sinusoids, bone matrix and adipocytes. In contrast, in aged bone, BM-MSCs show no preferential association with bone or adipocytes. Proliferative BM-MSCs are predominantly found along blood vessels. Moreover, we identify a specialized microenvironment for BM-MSCs in young bone, characterized by sinusoids coiled around trabeculae and enriched by R-type vessels. These findings provide insights into the native niches of BM-MSCs, offering a foundation for the development of tissue engineering strategies that mimic their physiological context.
- Open Access
- 26 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71310
Mapping individual molecular connectomes in Alzheimer's disease
INTRODUCTION: Mapping individual differences is crucial to improve personalized medicine approaches in Alzheimer's disease (AD), which is characterized by strong inter‐individual variability in the accumulation patterns of tau and amyloid beta pathology. METHODS: We assess the progression of AD across the disease continuum by building individual molecular connectomes using longitudinal positron emission tomography (PET) data. RESULTS: We demonstrate that these connectomes constitute a unique fingerprint, capable of identifying a single individual from a large group of subjects. Alterations in the connectomes discriminate different diagnostic groups and predict cognitive decline to a higher extent than conventional PET measures. We introduce a novel gene‐specific transcription network analysis that linked individual tau and amyloid connectomes to a common transcriptomic profile of apoptosis, with the tau connectome being specifically related to pyrimidine metabolism, and the amyloid connectome to histone acetylation. DISCUSSION: Individual molecular connectome mapping provides a novel and sensitive framework to monitor AD progression.
- 26 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71310
Open AccessMapping individual molecular connectomes in Alzheimer's disease
INTRODUCTION: Mapping individual differences is crucial to improve personalized medicine approaches in Alzheimer's disease (AD), which is characterized by strong inter‐individual variability in the accumulation patterns of tau and amyloid beta pathology. METHODS: We assess the progression of AD across the disease continuum by building individual molecular connectomes using longitudinal positron emission tomography (PET) data. RESULTS: We demonstrate that these connectomes constitute a unique fingerprint, capable of identifying a single individual from a large group of subjects. Alterations in the connectomes discriminate different diagnostic groups and predict cognitive decline to a higher extent than conventional PET measures. We introduce a novel gene‐specific transcription network analysis that linked individual tau and amyloid connectomes to a common transcriptomic profile of apoptosis, with the tau connectome being specifically related to pyrimidine metabolism, and the amyloid connectome to histone acetylation. DISCUSSION: Individual molecular connectome mapping provides a novel and sensitive framework to monitor AD progression.
- Open Access
- 18 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71170
Tracking early cognitive decline in preclinical AD with brain MRI similarity
INTRODUCTION: Early detection of neuroanatomical changes in preclinical Alzheimer's disease (AD) is critical for timely intervention. However, conventional magnetic resonance imaging (MRI) and fluid biomarkers often lack sensitivity to subtle structural alterations in early disease stages. METHODS: To identify early brain alterations, we applied a perturbation‐based brain similarity approach to cognitively normal participants from Alzheimer's Disease Neuroimaging Initiative (ADNI) and Open Access Series of Imaging Studies (OASIS), stratified by amyloid status. We evaluated its predictive performance for cognition and diagnostic conversion against cortical thickness, volumetric MRI, and fluid biomarkers. RESULTS: In both cohorts, brain similarity consistently outperformed other biomarkers across cognitive domains and amyloid groups. It also achieved superior accuracy in predicting clinical conversion and exhibited associations with cytoarchitectural organization. DISCUSSION: These findings highlight brain similarity as a sensitive marker of early neuroanatomical disruption in AD. Its ability to detect subtle structural changes before overt atrophy underscores its potential for early disease monitoring and treatment assessment in preclinical AD trials. Highlights: Brain similarity captures early brain changes in preclinical Alzheimer's disease (AD). Brain similarity outperforms conventional biomarkers such as cortical thickness, volume measures, and fluid biomarkers in predicting cognitive decline. Brain similarity predicts conversion to mild cognitive impairment and AD more accurately than traditional imaging markers, and its predictive performance is further improved when combined with fluid biomarkers. Brain similarity captures structural disruptions associated with cortical layer II of the cytoarchitectonic lamina of human neocortex.
- 18 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71170
Open AccessTracking early cognitive decline in preclinical AD with brain MRI similarity
INTRODUCTION: Early detection of neuroanatomical changes in preclinical Alzheimer's disease (AD) is critical for timely intervention. However, conventional magnetic resonance imaging (MRI) and fluid biomarkers often lack sensitivity to subtle structural alterations in early disease stages. METHODS: To identify early brain alterations, we applied a perturbation‐based brain similarity approach to cognitively normal participants from Alzheimer's Disease Neuroimaging Initiative (ADNI) and Open Access Series of Imaging Studies (OASIS), stratified by amyloid status. We evaluated its predictive performance for cognition and diagnostic conversion against cortical thickness, volumetric MRI, and fluid biomarkers. RESULTS: In both cohorts, brain similarity consistently outperformed other biomarkers across cognitive domains and amyloid groups. It also achieved superior accuracy in predicting clinical conversion and exhibited associations with cytoarchitectural organization. DISCUSSION: These findings highlight brain similarity as a sensitive marker of early neuroanatomical disruption in AD. Its ability to detect subtle structural changes before overt atrophy underscores its potential for early disease monitoring and treatment assessment in preclinical AD trials. Highlights: Brain similarity captures early brain changes in preclinical Alzheimer's disease (AD). Brain similarity outperforms conventional biomarkers such as cortical thickness, volume measures, and fluid biomarkers in predicting cognitive decline. Brain similarity predicts conversion to mild cognitive impairment and AD more accurately than traditional imaging markers, and its predictive performance is further improved when combined with fluid biomarkers. Brain similarity captures structural disruptions associated with cortical layer II of the cytoarchitectonic lamina of human neocortex.
- Open Access
Astrocyte-neuron mitochondrial transfer via mitoEVs supports neuronal energy metabolism and is impaired in early Alzheimer’s disease
Background: Mitochondrial dysfunction is an early and central feature of Alzheimer’s disease (AD). In particular, intercellular mitochondrial transfer has emerged as a mechanism of neuronal support in brain injury and neurodegeneration. However, pathways governing astrocyte-to-neuron transfer and its role in AD pathogenesis remain unknown. Methods: Using the App NL-G-F knock-in AD model, we combined high-resolution 4D live-cell imaging with quantitative fluorescence-based reporters to assess synaptic function and mitochondrial network dynamics in neurons and astrocytes. Direct and extracellular vesicle (EV)-restricted neuron-astrocyte co-culture systems were used to investigate bidirectional mitochondrial transfer. We performed the first in-depth structural, proteomic, and functional characterization of astrocyte-derived mitochondrial extracellular vesicles (mitoEVs) using cryo-electron microscopy, quantitative mass spectrometry, and bioenergetic analyses to define their cargo composition and metabolic effects. Results: We identified cell-type–specific mitochondrial remodeling in early AD, with compartmentalized synaptic energy deficits in neurons and hyperdynamic, less interconnected, yet metabolically preserved networks in astrocytes, preceding global bioenergetic decline. Bidirectional mitochondrial transfer between astrocytes and neurons, also at axonal terminals, was mediated by specialized mitoEVs but significantly reduced in the App NL-G-F model. Comprehensive proteomic and functional profiling revealed that WT astrocyte-derived mitoEVs are enriched in inner membrane and matrix proteins, supporting oxidative phosphorylation, lipid and amino acid metabolism, and redox homeostasis. In contrast, App NL-G-F mitoEVs are selectively depleted of respiratory and fatty acid oxidation components and exhibit impaired respiration with reduced Complex IV activity. Functionally, WT mitoEVs promote mobilization of abnormal accumulation of lipid droplets in App NL-G-F neurons, restore fatty acid oxidation, and increase neuronal bioenergetics, including at the synapses. In contrast, disease-derived mitoEVs fail to engage these pathways. Conclusions: Together, these findings identify mitoEV-mediated mitochondrial transfer as a glia-to-neuron metabolic pathway compromised in early AD and reveal a coordinated role for oxidative phosphorylation and fatty acid oxidation in supporting synaptic energy homeostasis.
Open AccessAstrocyte-neuron mitochondrial transfer via mitoEVs supports neuronal energy metabolism and is impaired in early Alzheimer’s disease
Background: Mitochondrial dysfunction is an early and central feature of Alzheimer’s disease (AD). In particular, intercellular mitochondrial transfer has emerged as a mechanism of neuronal support in brain injury and neurodegeneration. However, pathways governing astrocyte-to-neuron transfer and its role in AD pathogenesis remain unknown. Methods: Using the App NL-G-F knock-in AD model, we combined high-resolution 4D live-cell imaging with quantitative fluorescence-based reporters to assess synaptic function and mitochondrial network dynamics in neurons and astrocytes. Direct and extracellular vesicle (EV)-restricted neuron-astrocyte co-culture systems were used to investigate bidirectional mitochondrial transfer. We performed the first in-depth structural, proteomic, and functional characterization of astrocyte-derived mitochondrial extracellular vesicles (mitoEVs) using cryo-electron microscopy, quantitative mass spectrometry, and bioenergetic analyses to define their cargo composition and metabolic effects. Results: We identified cell-type–specific mitochondrial remodeling in early AD, with compartmentalized synaptic energy deficits in neurons and hyperdynamic, less interconnected, yet metabolically preserved networks in astrocytes, preceding global bioenergetic decline. Bidirectional mitochondrial transfer between astrocytes and neurons, also at axonal terminals, was mediated by specialized mitoEVs but significantly reduced in the App NL-G-F model. Comprehensive proteomic and functional profiling revealed that WT astrocyte-derived mitoEVs are enriched in inner membrane and matrix proteins, supporting oxidative phosphorylation, lipid and amino acid metabolism, and redox homeostasis. In contrast, App NL-G-F mitoEVs are selectively depleted of respiratory and fatty acid oxidation components and exhibit impaired respiration with reduced Complex IV activity. Functionally, WT mitoEVs promote mobilization of abnormal accumulation of lipid droplets in App NL-G-F neurons, restore fatty acid oxidation, and increase neuronal bioenergetics, including at the synapses. In contrast, disease-derived mitoEVs fail to engage these pathways. Conclusions: Together, these findings identify mitoEV-mediated mitochondrial transfer as a glia-to-neuron metabolic pathway compromised in early AD and reveal a coordinated role for oxidative phosphorylation and fatty acid oxidation in supporting synaptic energy homeostasis.
- Open Access
- 6 February 2026
- Published by Springer Nature in npj Aging
- Vol. 12 (1)
Similar minds age alike: an MRI similarity approach for predicting age-related cognitive decline
As individuals age, cortical alterations in brain structure contribute to cognitive decline. However, the specific patterns of age-related changes and their impact on cognition remain poorly understood. This study assessed the effects of aging on individual gray matter similarity networks and compared them to anatomical and functional connectivity networks derived from diffusion-weighted imaging and resting-state fMRI, respectively. Our results showed that gray matter similarity networks outperformed anatomical and functional connectivity in predicting age and cognition, showing the earliest age-related changes across the adult lifespan. These networks also demonstrated greater robustness to individual differences in cognition, behavior, and sex. Notably, age-related changes in gray matter similarity were associated with the brain’s underlying cytoarchitecture, being strongest in brain regions from cortical layers II and III. These findings provide a new biological insight into the neural mechanisms of cognitive aging and highlight the potential of individual morphological similarity for capturing complex brain changes across the lifespan.
- 6 February 2026
- Published by Springer Nature in npj Aging
- Vol. 12 (1)
Open AccessSimilar minds age alike: an MRI similarity approach for predicting age-related cognitive decline
As individuals age, cortical alterations in brain structure contribute to cognitive decline. However, the specific patterns of age-related changes and their impact on cognition remain poorly understood. This study assessed the effects of aging on individual gray matter similarity networks and compared them to anatomical and functional connectivity networks derived from diffusion-weighted imaging and resting-state fMRI, respectively. Our results showed that gray matter similarity networks outperformed anatomical and functional connectivity in predicting age and cognition, showing the earliest age-related changes across the adult lifespan. These networks also demonstrated greater robustness to individual differences in cognition, behavior, and sex. Notably, age-related changes in gray matter similarity were associated with the brain’s underlying cytoarchitecture, being strongest in brain regions from cortical layers II and III. These findings provide a new biological insight into the neural mechanisms of cognitive aging and highlight the potential of individual morphological similarity for capturing complex brain changes across the lifespan.
- Top Cited PapersOpen Access
- 29 January 2026
- Published by IOP Publishing in Journal of Physics: Photonics
- Vol. 8 (1) , 012501
Roadmap on deep learning for microscopy
Through digital imaging, microscopy has evolved from primarily being a means for visual observation of life at the micro- and nano-scale, to a quantitative tool with ever-increasing resolution and throughput. Artificial intelligence, deep neural networks, and machine learning (ML) are all niche terms describing computational methods that have gained a pivotal role in microscopy-based research over the past decade. This Roadmap encompasses key aspects of how ML is applied to microscopy image data, with the aim of gaining scientific knowledge by improved image quality, automated detection, segmentation, classification and tracking of objects, and efficient merging of information from multiple imaging modalities. We aim to give the reader an overview of the key developments and an understanding of possibilities and limitations of ML for microscopy. It will be of interest to a wide cross-disciplinary audience in the physical sciences and life sciences.
- 29 January 2026
- Published by IOP Publishing in Journal of Physics: Photonics
- Vol. 8 (1) , 012501
Top Cited PapersOpen AccessRoadmap on deep learning for microscopy
Through digital imaging, microscopy has evolved from primarily being a means for visual observation of life at the micro- and nano-scale, to a quantitative tool with ever-increasing resolution and throughput. Artificial intelligence, deep neural networks, and machine learning (ML) are all niche terms describing computational methods that have gained a pivotal role in microscopy-based research over the past decade. This Roadmap encompasses key aspects of how ML is applied to microscopy image data, with the aim of gaining scientific knowledge by improved image quality, automated detection, segmentation, classification and tracking of objects, and efficient merging of information from multiple imaging modalities. We aim to give the reader an overview of the key developments and an understanding of possibilities and limitations of ML for microscopy. It will be of interest to a wide cross-disciplinary audience in the physical sciences and life sciences.
- Open Access
- 20 August 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1
Correction: Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease
- 20 August 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1
Open AccessCorrection: Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease
- Open Access
- 20 June 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-20
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease
Background: Parkinson’s disease (PD) is a highly heterogeneous disorder with distinct phenotypes that can develop well before motor symptoms appear. Recently, two main phenotypes based on the different pathological spreading patterns of PD have been proposed: “body-first”, where α-synuclein pathology begins in the peripheral nervous system and spreads symmetrically from bottom-up, and “brain-first”, where pathology starts in the brain and spreads asymmetrically downwards. However, no studies have assessed these phenotypes across both prodromal and clinical PD stages, tracked their pathological progression in vivo or identified potential underlying biological mechanisms. Methods: To address this, we analyzed 910 prodromal and 1120 clinical PD cases with comprehensive longitudinal clinical, imaging, and genetic data from the Parkinson Progression Marker Initiative over a 12-year period. Results: Our findings revealed that both prodromal and clinical groups with body-first symptoms exhibited greater motor dysfunction, anxiety, and depression at baseline; as well as worse longitudinal motor progression and attention decline compared to brain-first cases. The body-first and brain-first phenotypes were stable over time and predicted conversion to clinical PD in prodromal cases, and were also found using unsupervised deep learning analyses. Additionally, body-first cases displayed more pronounced changes in the caudal LC, as well as symmetrical alterations in the striatum and glymphatic system, consistent with the traditional bottom-up progression described by Braak’s staging of α-synuclein pathology and the more symmetric distribution proposed for body-first PD. In contrast, brain-first cases exhibited changes in the rostral LC and asymmetric alterations in the striatum and glymphatic system, suggesting a top-down progression. Genetic analysis also identified new specific single nucleotide polymorphisms associated with PD phenotypes, such as TRIM40 and IP6K2 , linked to worse motor and cognitive outcomes in prodromal cases. Conclusions: These findings emphasize the importance of recognizing body-first and brain-first PD as distinct entities with unique clinical, imaging, and genetic profiles, paving the way for targeted and personalized therapeutic strategies that address the specific pathophysiological mechanisms of PD.
- 20 June 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-20
Open AccessClinical progression and genetic pathways in body-first and brain-first Parkinson’s disease
Background: Parkinson’s disease (PD) is a highly heterogeneous disorder with distinct phenotypes that can develop well before motor symptoms appear. Recently, two main phenotypes based on the different pathological spreading patterns of PD have been proposed: “body-first”, where α-synuclein pathology begins in the peripheral nervous system and spreads symmetrically from bottom-up, and “brain-first”, where pathology starts in the brain and spreads asymmetrically downwards. However, no studies have assessed these phenotypes across both prodromal and clinical PD stages, tracked their pathological progression in vivo or identified potential underlying biological mechanisms. Methods: To address this, we analyzed 910 prodromal and 1120 clinical PD cases with comprehensive longitudinal clinical, imaging, and genetic data from the Parkinson Progression Marker Initiative over a 12-year period. Results: Our findings revealed that both prodromal and clinical groups with body-first symptoms exhibited greater motor dysfunction, anxiety, and depression at baseline; as well as worse longitudinal motor progression and attention decline compared to brain-first cases. The body-first and brain-first phenotypes were stable over time and predicted conversion to clinical PD in prodromal cases, and were also found using unsupervised deep learning analyses. Additionally, body-first cases displayed more pronounced changes in the caudal LC, as well as symmetrical alterations in the striatum and glymphatic system, consistent with the traditional bottom-up progression described by Braak’s staging of α-synuclein pathology and the more symmetric distribution proposed for body-first PD. In contrast, brain-first cases exhibited changes in the rostral LC and asymmetric alterations in the striatum and glymphatic system, suggesting a top-down progression. Genetic analysis also identified new specific single nucleotide polymorphisms associated with PD phenotypes, such as TRIM40 and IP6K2 , linked to worse motor and cognitive outcomes in prodromal cases. Conclusions: These findings emphasize the importance of recognizing body-first and brain-first PD as distinct entities with unique clinical, imaging, and genetic profiles, paving the way for targeted and personalized therapeutic strategies that address the specific pathophysiological mechanisms of PD.